DIN ISO 13022:2014-06 (E)

Medical products containing viable human cells - Application of risk management and requiremen ts for processing practices (ISO 13022:2012)

Contents

Page

National foreword 3

National Annex NA (informative) Correction of Figure B.1 4

National Annex N (informative) Bibliography 5

Introduction 6

1 Scope 7

2 Normative references 8

3 Terms and definitions 8

4 Risk management process 12
4.1 General 12
4.2 Hazards associated with the cellular component 12
4.3 Risk analysis 14
4.4 Risk evaluation 15
4.5 Risk control 15
4.6 Evaluation of overall residual risk acceptability 15
4.7 Production and post-production information system 16

Annex B (informative) Graphic representation of the part of the risk management process for cell-based medical products 18

Annex C (normative) Requirements for donor selection and testing 19

Annex D (informative) Guidance for tissue procurement 23

Annex E (normative) Requirements for handling of cells and tissue during manufacture 26

Annex F (normative) Requirements for packaging and labelling 29

Annex G (informative) Guidance for transport 32

Annex H (informative) Guidance for storage 37

Annex I (normative) Requirements for traceability 40

Annex J (normative) Risk reduction measures related to contamination with viruses and other infectious agents such as TSE 41

Annex K (informative) Guidance with regard to hazards caused by the tumorigenic potential of the human cells/tissues used for the production of medical products 44

Annex L (informative) Guidance with regard to microbiological contamination 45

Annex M (informative) Guidance with regard to potential adverse effects of non-cellular residues of the product 46

Annex N (normative) Requirements with regard to potential adverse effects of the cellular components of a medical product 47

Annex O (informative) Guidance for the characterization of the cellular components of a medical product 48

Annex P (informative) Clinical evaluation and testing 51

Bibliography 52